

Application Serial No. 09/455,543

1. [Amended] A pharmaceutical composition for the treatment of soft tissue cancer in mammals comprising a pharmaceutically effective amount of at least one compound selected from the group consisting of aldehyde C16 (pure), amyl cinnamic aldehyde, amyl salicylate, anisic aldehyde, benzyl alcohol, benzyl acetate, cinnamaldehyde, cinnamic alcohol,  $\alpha$ -terpineol, carvacrol, carveol, citral, citronellal, citronellol, p-cymene, diethyl phthalate, dimethyl salicylate, dipropylene glycol, eucalyptol (cineole), eugenol, iso-eugenol, galaxolide, geraniol, guaiacol, ionone, d-limonene, menthol, methyl anthranilate, methyl ionone, methyl salicylate,  $\alpha$ -phellandrene, pennyroyal oil, perillaldehyde, 1- or 2-phenyl ethyl alcohol, 1- or 2-phenyl ethyl propionate, piperonal, piperonyl acetate, piperonyl alcohol, D-pulegone, terpinen-4-ol, terpinyl acetate, 4-tert butylcyclohexyl acetate, thyme oil, thymol, metabolites of trans-anethole, vanillin, and ethyl vanillin, and at least one signal transduction modulator selected from the group consisting of cyclic adenosine monophosphate (cAMP), cAMP-dependent protein kinase, tyrosine kinase, calcium phospholipid-dependent protein kinase (PKC), mitogen activated protein kinase family members, calcium-calmodulin-dependent protein kinase, and growth factor receptor inhibitors.

Sub C<sup>3</sup>  
6. [Amended] The pharmaceutical composition of claim 1, wherein the compound is eugenol.

7. [Amended] The pharmaceutical composition of claim 1, wherein the compound is thymol.

8. [Amended] The pharmaceutical composition of claim 1, wherein the compound is isoeugenol.

Application Serial No. 09/455,543

Sub (3)  
cont.

9. [Amended] The pharmaceutical composition of claim 1, wherein the compound is benzyl alcohol.

10. [Amended] The pharmaceutical composition of claim 1, wherein the compound is carvacrol.

11. [Amended] The pharmaceutical composition of claim 1, wherein the compound is cinnamic alcohol.

12. [Amended] The pharmaceutical composition of claim 1, wherein the compound is cinnamic aldehyde.

13. [Amended] The pharmaceutical composition of claim 1, wherein the compound is citronellal.

14. [Amended] The pharmaceutical composition of claim 1, wherein the compound is trans-anethole.

**Please add claim 16, as follows:**

Sub C\*  
~~--16. The pharmaceutical composition of claim 1, wherein the compound is  $\alpha$ -terpineol.--~~

**REMARKS**

Claims 3-4 are canceled without prejudice or disclaimer. Claims 1 and 6-14 are amended to clarify the subject matter sought to be patented. Claim 16 is added. Claim 15 is withdrawn. Claims 1 and 5-16 are pending. No new matter has been added.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version With Markings To Show Changes Made."